GlassScriptPhysician profile
Indira Bollampally
NPI 1609856913
$1,489.49
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $143 · 2021: $292 · 2022: $298.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $485.84 | 2019-2022 | |
| Glaxosmithkline, LLC. | $285.91 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $212.85 | 2019-2022 | |
| Mylan Specialty L.P. | $144.65 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.48 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $111.87 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $44.86 | 2019 | |
| Circassia INC. | $25.06 | 2019 | |
| Electromed, INC. | $14.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.76 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indira Bollampally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.